Telithromycin

Ketolide Antibacterial — ANTIINFECTIVES FOR SYSTEMIC USE

Key facts

Telithromycin is an ofm drug in the Ketolide Antibacterial class catalogued in DrugCentral. It was first approved by the FDA in 2004. DrugCentral lists 1 molecular target, including KCNH2. Recorded indications include Chlamydial pneumonia, Haemophilus influenzae pneumonia, Moraxella Catarrhalis Pneumonia and Pneumococcal pneumonia.

• Approval status: ofm (first approved 2004 by the FDA).
• Drug class: Ketolide Antibacterial.
• Molecular targets: KCNH2 (1 listed in DrugCentral).
• Indications: Chlamydial pneumonia, Haemophilus influenzae pneumonia, Moraxella Catarrhalis Pneumonia, Pneumococcal pneumonia and Pneumonia due to Mycoplasma pneumoniae and others.
• ATC code: J01FA15 (Macrolides).
• Molecular formula: C43H65N5O10; molecular weight 812.02 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (7)

• Chlamydial pneumonia
• Haemophilus influenzae pneumonia
• Moraxella Catarrhalis Pneumonia
• Pneumococcal pneumonia
• Pneumonia due to Mycoplasma pneumoniae
• Streptococcus pyogenes infection
• Tonsillitis due to Streptococcus Pyogenes

Contraindications (10)

• Congenital long QT syndrome
• Diarrhea
• Disease of liver
• Drug-induced hepatitis
• Hypokalemia
• Hypomagnesemia
• Myasthenia gravis
• Prolonged QT interval
• Pseudomembranous enterocolitis
• Torsades de pointes

Mechanism & targets

• Established pharmacologic class: Ketolide Antibacterial

Molecular targets (1)

Target	Gene	Action	Activity
Potassium voltage-gated channel subfamily H member 2	KCNH2	unknown	IC50 4.40

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
2004-04-01	FDA	—	SANOFI AVENTIS US

ATC classification

ATC code	Therapeutic hierarchy
J01FA15	ANTIINFECTIVES FOR SYSTEMIC USE › ANTIBACTERIALS FOR SYSTEMIC USE › MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS › Macrolides

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Drug hypersensitivity	82.9

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Telithromycin is on its molecule page.

• Molecular formula: C₄₃H₆₅N₅O₁₀
• Molecular weight: 812.02 g/mol
• CAS number: —
• InChIKey: LJVAJPDWBABPEJ-PNUFFHFMSA-N
• PubChem CID: 3002190

CC[C@H]1OC(=O)[C@H](C)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@H]2N(CCCCN3C=NC(=C3)C3=CN=CC=C3)C(=O)O[C@]12C)OC

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Telithromycin used for?

DrugCentral lists the following indications for Telithromycin: Chlamydial pneumonia, Haemophilus influenzae pneumonia, Moraxella Catarrhalis Pneumonia, Pneumococcal pneumonia, Pneumonia due to Mycoplasma pneumoniae, Streptococcus pyogenes infection and Tonsillitis due to Streptococcus Pyogenes.

How does Telithromycin work?

Its molecular targets in DrugCentral include KCNH2.

When was Telithromycin first approved?

Telithromycin was first approved by the FDA in 2004.

What drug class does Telithromycin belong to?

Telithromycin is in the Ketolide Antibacterial class.

What is the chemical formula of Telithromycin?

Telithromycin has the molecular formula C43H65N5O10 and a molecular weight of 812.02 g/mol.

Sources

• DrugCentral drug card 2581 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1136 — compound record and bioactivity
• PubChem CID 3002190 — chemical identifiers
• DrugBank DB00976 — drug record
• FDA UNII KI8H7H19WL — substance identity
• DailyMed: FDA labels for Telithromycin — current prescribing information (label search)
• UniProt Q12809 (KCNH2) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.